Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul;57(7):1183-1186.
doi: 10.1038/s41409-022-01675-w. Epub 2022 Apr 21.

Neutralizing antibody and T cell responses to SARS-CoV-2 vaccination in hematopoietic cell transplant recipients

Eleni Gavriilaki #  1 , Anastasia Papadopoulou #  1 , Tasoula Touloumenidou  1 , Fani Stavridou  1 , Evaggelia-Evdoxia Koravou  1 , Maria Giannaki  1 , Apostolia Papalexandri  1 , Georgios Karavalakis  1 , Ioannis Batsis  1 , Andreas Kourelis  2 , Fani Chatzopoulou  2 , Dimitrios Chatzidimitriou  2 , Damianos Sotiropoulos  1 , Evangelia Yannaki  3 , Ioanna Sakellari  1 , Achilles Anagnostopoulos  1
Affiliations

Neutralizing antibody and T cell responses to SARS-CoV-2 vaccination in hematopoietic cell transplant recipients

Eleni Gavriilaki et al. Bone Marrow Transplant. 2022 Jul.
No abstract available

PubMed Disclaimer

Conflict of interest statement

EG has consulted for Amyndas, Alexion, Omeros, and Sanofi Pharmaceuticals. EY has consulted for BlueBirdBio and Vertex/CrispRTherapeutics. Remaining authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Humoral and T cell responses in HCT recipients.
A Humoral and T cell responses after the second vaccination dose as compared to the first dose in HCT recipients. The red and blue dotted lines in the left graph indicate the 30% and 50% threshold above which CoV-2-NAbs are considered positive or highly protective, respectively. The blue dotted line in the middle graph indicates the threshold above which T cell response was considered positive. Median with 95% CI is shown. ****p < 0.0001, **p = 0.002. B CoV-2-NAbs and spike-STs after the second dose in healthy subjects, auto- and allo-HCT recipients, as well as the allo-HCT subgroups, on and off immunosuppression. The red and blue dotted lines in the left graph indicate the 30% and 50% threshold above which CoV-2-NAbs are considered positive and have been associated with clinically relevant viral inhibition, respectively. The blue dotted line in the right graph indicates the threshold above which T cell response was considered positive. Median with 95% CI is shown. ****p < 0.0001, ***p = 0.0005, **p = 0.0044. C Humoral protective immune responses after the 1st and 2nd vaccination dose in allo-HCT patients. Each line represents a single allo-HCT patient. The red dotted line indicates the 30% threshold above which CoV-2-NAbs are considered positive. D Association of circulating CD3+ cells <1000/μl with neutralization capacity and levels of spike-STs. Median with 95% CI is shown. **p = 0.0029, *p = 0.0292. HCT hematopoietic cell transplantation, Auto-HCT autologous HCT, Allo-HCT allogeneic HCT, CoV-2-NAbs neutralizing antibodies against SARS-CoV-2, spike-STs SARS-CoV-2 spike-specific T cells.
See this image and copyright information in PMC

References

    1. Sharma A, Bhatt NS, Martin AS, Abid MB, Bloomquist J, Chemaly RF, et al. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. Lancet Haematol. 2021;8:e185–e193. doi: 10.1016/S2352-3026(20)30429-4. - DOI - PMC - PubMed
    1. Shah GL, DeWolf S, Lee YJ, Tamari R, Dahi PB, Lavery JA, et al. Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation. J Clin Invest. 2020;130:6656–67. doi: 10.1172/JCI141777. - DOI - PMC - PubMed
    1. Coll E, Fernández-Ruiz M, Sánchez-Álvarez JE, Martínez-Fernández JR, Crespo M, Gayoso J, et al. COVID-19 in transplant recipients: The Spanish experience. Am J Transpl. 2021;21:1825–37. doi: 10.1111/ajt.16369. - DOI - PMC - PubMed
    1. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603–15. doi: 10.1056/NEJMoa2034577. - DOI - PMC - PubMed
    1. Sattler A, Schrezenmeier E, Weber UA, Potekhin A, Bachmann F, Straub-Hohenbleicher H, et al. Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients. J Clin Invest. 2021;131:e150175. doi: 10.1172/JCI150175. - DOI - PMC - PubMed

Publication types